Healtcare ALK Positive Lung Cancer Treatment Market | Page 2

ALK Positive Lung Cancer Treatment Market Restraints
Development of rapid resistance to drugs is expected to limit growth of the ALK positive lung
cancer treatment market. For instance, according to an Oncology Live February 2018 report, major
challenge in drug development is rapid growth in resistance, which is responsible for slow patient
recovery from disease. Moreover, according to an article published in Cancers journal, in August
2017, the mechanisms for resistance in drugs is tyrosine kinase mutations, and Epidermal Growth
Factor Receptor (EGFR) activation. These bypass mechanisms of resistance are aggravating tumor
cells, which in turn is restraining growth of the market.
ALK Positive Lung Cancer Treatment Market – Regional Analysis
On the basis of region, the global ALK positive lung cancer treatment market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America
region is expected to witness significant growth in the market, owing to increasing number of
clinical trials operating in the U.S. For instance, TP Therapeutics, Inc., is undergoing clinical trial
for TPX-0005 drug for treating ALK mutations. The study is expected to complete in December
2021.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/alk-
positive-lung-cancer-treatment-market-2201
Asia Pacific region is expected to witness the significant growth in the market, owing to increasing
use of tobacco and smoking leading to lung cancer. According to an article published in Eastern
Journal of medical Sciences 2017, lung cancer contributes around 6.8% of all cancers in India,
representing the significant burden of lung cancer on country, which is contributing towards the
cancer morbidity and mortality.
Global Key Players:
Key players operating in ALK positive lung cancer treatment market include F. Hoffmann-La
Roche Ltd., Pfizer Inc., Novartis AG, TP Therapeutics, Inc., Bristol-Myers Squibb Company, and
Eli Lilly and Company.
ALK Positive Lung Cancer Treatment Market – Taxonomy
By Drug
Crizotinib,Alectinib,Brigatinib,Ceritinib
By Distribution Channel
Hospital Pharmacies,Retail Pharmacies,Clinics